About: Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
Creator	Meini, Simone Pecori, Davide Tascini, Carlo Longo, Benedetta Pagotto, Alberto Vendramin, Igor
source	Medline; PMC
abstract	A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first phase, when the viral replication plays a pivotal pathogenetic role, antiviral drugs could be crucial in limiting viral-induced organ damage. Unfortunately, there are no specific antivirals of proven efficacy for COVID-19, and several drugs have been repurposed to face this dramatic pandemic. In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). We searched PubMed to identify all relevant clinical and laboratory studies published up to 15 May 2020; the guidelines on the use of LPV/r in COVID-19 were further directly searched on the website of the main international scientific societies and agencies. Available evidence is currently scarce and of low quality. The recommendations issued for COVID-19 vary from positions clearly against the use of LPV/r to other positions that are more favorable. In our opinion, despite the controversial results of an important randomized clinical trial, and some recommendations, clinicians should not abandon the use of LPV/r for the treatment of COVID-19, possibly using this drug inside a prospective randomized trial, waiting for the results of the numerous ongoing trials evaluating its efficacy.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.3390/jcm9072050
bibo:pmid	32629768
has license	cc-by
sha1sum (hex)	ab10efadcbf12ffea4252cf2dd644bf017e70fd2
schema:url	https://doi.org/10.3390/jcm9072050
resource representing a document's title	Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
has PubMed Central identifier	PMC7408758
has PubMed identifier	32629768
schema:publication	J Clin Med
resource representing a document's body	covid:ab10efadcbf12ffea4252cf2dd644bf017e70fd2#body_text
is schema:about of	named entity '2019' named entity 'DIRECTLY' named entity 'COVID-19' named entity 'CLINICAL' named entity 'PUBLISHED' named entity 'SPECIFIC' named entity 'DUE TO' named entity 'EFFICACY' named entity 'SEARCHED' named entity 'ANTIVIRALS' named entity 'EVIDENCE' named entity 'USING' named entity 'VIRAL-' named entity 'ITS' named entity 'SOCIETIES' named entity 'LOPINAVIR' named entity 'USE OF' named entity 'PANDEMIC' named entity 'DRUGS' named entity 'FIRST PHASE' covid:arg/ab10efadcbf12ffea4252cf2dd644bf017e70fd2 named entity 'diarrhea' named entity 'nausea' named entity 'arbidol' named entity 'COVID' named entity 'respiratory illness' named entity 'severe acute respiratory syndrome' named entity 'COVID' named entity 'COVID' named entity 'randomized clinical trial' named entity 'randomized trial' named entity 'life-threatening' named entity 'SARS' named entity 'PubMed' named entity 'organ damage' named entity 'Lopinavir/Ritonavir' named entity 'Covid-19' named entity 'RCT' named entity 'SARS-CoV-2' named entity 'antiviral agents' named entity 'antiviral drugs' named entity 'COVID' named entity 'drug target' named entity 'COVID' named entity 'enzyme' named entity 'HIV' named entity 'MERS-CoV' named entity 'protease' named entity 'protease' named entity 'antiviral' named entity 'protease' named entity 'HIV infection' named entity 'subgroup analysis' named entity 'cohort study' named entity 'SARS-CoV-2' named entity 'proteolytic processing' named entity 'aspartate protease' named entity 'intErferon-β' named entity 'statistically significant' named entity 'LPV' named entity 'antivirals' named entity 'COVID' named entity 'Wuhan' named entity 'antiviral' named entity 'steroid' named entity 'retrospective study' named entity 'LPV' named entity 'COVID' named entity 'RCT' named entity 'self-limiting' named entity 'standard treatment' named entity 'intubation' named entity 'LPV' named entity 'ARDS' named entity 'methylprednisolone' named entity 'pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software